Lainie P Martin
Overview
Explore the profile of Lainie P Martin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1508
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reibel J, Sun L, Parikh R, Mahmud N, Martin L, Hubbard R, et al.
J Natl Cancer Inst
. 2024 Dec;
PMID: 39658317
The recent cisplatin and carboplatin ("platinum") chemotherapy shortage, first announced on February 10, 2023, has impacted cancer patients nationwide. Here, we quantify the extent to which the shortage affected platinum...
2.
Landen C, Buckanovich R, Sill M, Mannel R, Walker J, DiSilvestro P, et al.
J Clin Oncol
. 2024 May;
42(21):2537-2545.
PMID: 38776484
Purpose: The interleukin-6/Janus kinase (JAK)/signal transducers and activators of transcription 3 axis is a reported driver of chemotherapy resistance. We hypothesized that adding the JAK1/2 inhibitor ruxolitinib to standard chemotherapy...
3.
Richardson D, Moore K, Vergote I, Gilbert L, Martin L, Mantia-Smaldone G, et al.
Gynecol Oncol
. 2024 Mar;
185:186-193.
PMID: 38447347
Objective: Evaluate the antitumor activity and safety profile of the triplet combination of mirvetuximab soravtansine (MIRV), carboplatin, and bevacizumab in recurrent, platinum-sensitive ovarian cancer. Methods: Participants with recurrent, platinum-sensitive epithelial...
4.
Moore K, Angelergues A, Konecny G, Garcia Y, Banerjee S, Lorusso D, et al.
N Engl J Med
. 2023 Dec;
389(23):2162-2174.
PMID: 38055253
Background: Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United States. Methods: We conducted a...
5.
Pantel A, Gitto S, Makvandi M, Kim H, Medvedv S, Weeks J, et al.
Clin Cancer Res
. 2022 Nov;
29(8):1515-1527.
PMID: 36441795
Purpose: PARP inhibitors have become the standard-of-care treatment for homologous recombination deficient (HRD) high-grade serous ovarian cancer (HGSOC). However, not all HRD tumors respond to PARPi. Biomarkers to predict response...
6.
Shah P, Wethington S, Pagan C, Latif N, Tanyi J, Martin L, et al.
Gynecol Oncol
. 2021 Oct;
163(2):246-253.
PMID: 34620496
Objective: Platinum-resistant, high-grade serous ovarian cancer (HGSOC) has limited treatment options. Preclinical data suggest that poly(ADP-ribose) polymerase inhibitors (PARPi) and ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) are synergistic. CAPRI...
7.
Hatch R, Patel S, Cambareri C, Uritsky T, Martin L
J Oncol Pharm Pract
. 2021 Jun;
28(5):1102-1110.
PMID: 34134553
Introduction: Poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) have become a cornerstone of therapy in the management ovarian cancer and other cancers. PARPi are associated with significant toxicities and management strategies...
8.
OMalley D, Matulonis U, Birrer M, Castro C, Gilbert L, Vergote I, et al.
Gynecol Oncol
. 2020 Feb;
157(2):379-385.
PMID: 32081463
Purpose: To evaluate the safety and clinical activity of mirvetuximab soravtansine, an antibody-drug conjugate comprising a humanized anti-folate receptor alpha (FRα) monoclonal antibody, cleavable linker, and the maytansinoid DM4, a...
9.
Westin S, Sill M, Coleman R, Waggoner S, Moore K, Mathews C, et al.
Gynecol Oncol
. 2019 Oct;
155(3):420-428.
PMID: 31623857
Objective: We sought to determine safety and efficacy of the AKT inhibitor, GSK2141795, combined with the MEK inhibitor, trametinib, in endometrial cancer. Methods: Patients with measurable recurrent endometrial cancer were...
10.
Birrer M, Betella I, Martin L, Moore K
Oncologist
. 2019 Jan;
24(4):425-429.
PMID: 30635448
Prognosis for women with epithelial ovarian cancer remains poor. One new molecular target in epithelial ovarian cancer is folate receptor alpha (FRα). This commentary discusses the characteristics that contribute to...